Other approaches to depleting tumor-associated macrophages may be possible, such as antibodies against triggering receptor expressed on myeloid cells 2 (TREM2), or TREM1 to reprogram of immunosuppressive myeloid cells [19, 20], though safety concerns will have to be addressed before this class of agents progresses. The gene discussed is TREM2; the disease is neoplasm.